Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6121596 | Journal of Clinical Virology | 2012 | 4 Pages |
Abstract
The rate of SVR to pegIFN/RBV therapy tends to be lower in HIV-infected patients with chronic hepatitis C due to HCV-1a than HCV-1b; being the impact of IL28B variants significantly stronger on HCV-1a than HCV-1b.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Eugenia Vispo, Norma I. Rallon, Pablo Labarga, Pablo Barreiro, Jose Miguel Benito, Vincent Soriano,